IPO
The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.
Tempus AI Prices $410.7M Initial Public Offering
The oncology data company priced its initial public offering of 11.1 million shares at $37.00 per share.
Boundless Bio Prices $100M Initial Public Offering
The firm will use the proceeds to advance its two clinical candidates targeting ecDNA and to fund development of its diagnostic and a third ecDNA drug program.
Kyverna Therapeutics, Autoimmune Disease CAR T-Cell Therapy Developer, Files to Go Public
Kyverna's lead candidate is an autologous cell therapy being studied in refractory lupus nephritis and other rheumatology and neurology indications.
Cargo Therapeutics Prices Common Stock Offering Expected to Bring in Over $281M
The firm plans to use the proceeds to advance its next-generation cell therapies, including its autologous, CD22-directed CAR T-cell candidate CRG-022.
Sep 20, 2023
RayzeBio Raises $358M in Initial Public Offering
Oct 27, 2022
Jul 14, 2022
South Korean Biotech Lunit Prices $28M IPO
Oct 8, 2021